All In Biotech

Drug Trial Radar · NCT04914351

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours

A Phase Ⅰ, Multi-center, Open-label, Single-arm, Dose Escalation, First-in-human Clinical Study of HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours

Last checked: Nov 19, 2026Latest source record: Mar 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

17

Actual

Start

May 3, 2022

Primary completion

Nov 27, 2023

Study completion Dec 30, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, first-in-human trial to evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 administered intravenously (IV) once every two weeks in adult patients with locally advanced/metastatic malignant solid tumors.

Conditions

  • Locally Advanced/Metastatic Solid Tumors

Interventions

  • HY-0102Drug

    Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Drug Limited Toxicities (DLTs)Time frame: From Time of First dose through DLT observation period, 28 days
  2. Incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs).Time frame: From the start of treatment until up to 90 days after the last dose of study drug
  3. Number of patients with changes in laboratory parameters from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
  4. Number of patients with changes in electrocariogram (ECG) from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
  5. Number of participants with changes in left ventricular ejection fraction (LVEF) from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug
  6. Number of participants with changes in Clinically Significant Vital Sign from baselineTime frame: From the start of treatment until up to 30(±7) days after the last dose of study drug

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute

    Orlando, Florida

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Texas Oncology

    Tyler, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.